Shedding of HIV-1 in semen during primary infection.

PubWeight™: 0.84‹?›

🔗 View Article (PMID 9084808)

Published in AIDS on March 15, 1997

Authors

J R Dyer, B L Gilliam, J J Eron, M S Cohen, S A Fiscus, P L Vernazza

Articles by these authors

A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med (1997) 17.51

Dynamic magnetic resonance imaging of human brain activity during primary sensory stimulation. Proc Natl Acad Sci U S A (1992) 16.64

Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med (1997) 10.62

Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature (2012) 7.76

Functional mapping of the human visual cortex by magnetic resonance imaging. Science (1991) 6.93

Sexual transmission of HIV. N Engl J Med (1997) 6.84

Patterns of brain activation in people at risk for Alzheimer's disease. N Engl J Med (2000) 6.72

Reduction of concentration of HIV-1 in semen after treatment of urethritis: implications for prevention of sexual transmission of HIV-1. AIDSCAP Malawi Research Group. Lancet (1997) 6.34

Potent antiretroviral treatment of HIV-infection results in suppression of the seminal shedding of HIV. The Swiss HIV Cohort Study. AIDS (2000) 4.91

Viral burden in genital secretions determines male-to-female sexual transmission of HIV-1: a probabilistic empiric model. AIDS (2001) 4.76

Optic nerve decompression may improve the progressive form of nonarteritic ischemic optic neuropathy. Arch Ophthalmol (1989) 4.48

Quantitating the multiplicity of infection with human immunodeficiency virus type 1 subtype C reveals a non-poisson distribution of transmitted variants. J Virol (2009) 4.40

Characterization of V3 sequence heterogeneity in subtype C human immunodeficiency virus type 1 isolates from Malawi: underrepresentation of X4 variants. J Virol (1999) 4.16

Use of evolutionary limitations of HIV-1 multidrug resistance to optimize therapy. Nature (1993) 3.73

Maximizing sensitivity and specificity of PCR by pre-amplification heating. Nucleic Acids Res (1991) 3.56

High levels of human immunodeficiency virus type 1 in blood and semen of seropositive men in sub-Saharan Africa. J Infect Dis (1998) 3.46

Effect of antiviral treatment on the shedding of HIV-1 in semen. AIDS (1997) 3.42

ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results. AIDS (2001) 3.35

The microbicidal mechanisms of human neutrophils and eosinophils. Rev Infect Dis (1981) 3.29

Trichomonas vaginalis as a cause of urethritis in Malawian men. Sex Transm Dis (1999) 3.12

Mechanism of the luminol-dependent chemiluminescence of human neutrophils. J Immunol (1982) 3.11

Azithromycin for empirical treatment of the nongonococcal urethritis syndrome in men. A randomized double-blind study. JAMA (1995) 2.71

Preventing sexual transmission of HIV--new ideas from sub-Saharan Africa. N Engl J Med (2000) 2.67

Sexual transmission of HIV: infectiousness and prevention. AIDS (1999) 2.59

Quantification of HIV in semen: correlation with antiviral treatment and immune status. AIDS (1997) 2.51

Bacterial adaptation to oxidative stress: implications for pathogenesis and interaction with phagocytic cells. FASEB J (1989) 2.47

Trichomoniasis: clinical manifestations, diagnosis and management. Sex Transm Infect (2004) 2.43

Acute HIV infection: impact on the spread of HIV and transmission of drug resistance. AIDS (2001) 2.42

The transferrin receptor expressed by gonococcal strain FA1090 is required for the experimental infection of human male volunteers. Mol Microbiol (1998) 2.33

Fungal infection in chronic granulomatous disease. The importance of the phagocyte in defense against fungi. Am J Med (1981) 2.31

Resistance to 2',3'-dideoxycytidine conferred by a mutation in codon 65 of the human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother (1994) 2.24

Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1-infected adults treated with combination antiretroviral therapy. Swiss HIV Cohort Study. N Engl J Med (1999) 2.17

Functional cerebral imaging by susceptibility-contrast NMR. Magn Reson Med (1990) 2.14

Quantitation of human immunodeficiency virus type 1 RNA in cell free seminal plasma: comparison of NASBA with Amplicor reverse transcription-PCR amplification and correlation with quantitative culture. J Virol Methods (1996) 2.12

Response of Pseudomonas aeruginosa to pyocyanin: mechanisms of resistance, antioxidant defenses, and demonstration of a manganese-cofactored superoxide dismutase. Infect Immun (1992) 2.09

HIV in body fluids during primary HIV infection: implications for pathogenesis, treatment and public health. AIDS (2001) 2.08

Closed reduction and percutaneous pinning of fractures of the proximal phalanx. J Hand Surg Br (2001) 2.07

Evolutionary variants of the human immunodeficiency virus type 1 V3 region characterized by using a heteroduplex tracking assay. J Virol (1997) 2.04

Cloning and characterization of the Pseudomonas aeruginosa sodA and sodB genes encoding manganese- and iron-cofactored superoxide dismutase: demonstration of increased manganese superoxide dismutase activity in alginate-producing bacteria. J Bacteriol (1993) 2.03

Second-line treatment in the Malawi antiretroviral programme: high early mortality, but good outcomes in survivors, despite extensive drug resistance at baseline. HIV Med (2010) 2.00

Drug resistance and virologic response in NUCA 3001, a randomized trial of lamivudine (3TC) versus zidovudine (ZDV) versus ZDV plus 3TC in previously untreated patients. AIDS (1996) 1.96

Multiple gonococcal pilin antigenic variants are produced during experimental human infections. J Clin Invest (1994) 1.93

Two-drug combinations of zidovudine, didanosine, and recombinant interferon-alpha A inhibit replication of zidovudine-resistant human immunodeficiency virus type 1 synergistically in vitro. J Infect Dis (1991) 1.93

Qualitative and quantitative evaluation of six algorithms for correcting intensity nonuniformity effects. Neuroimage (2001) 1.90

Brain parenchyma motion: measurement with cine echo-planar MR imaging. Radiology (1992) 1.90

Breakthrough pneumococcal bacteremia in patients being treated with azithromycin and clarithromycin. Clin Infect Dis (2000) 1.89

3-year suppression of HIV viremia with indinavir, zidovudine, and lamivudine. Ann Intern Med (2000) 1.88

Standardized microtiter assay for determination of syncytium-inducing phenotypes of clinical human immunodeficiency virus type 1 isolates. J Clin Microbiol (1994) 1.85

Gonococcal infection: a model of molecular pathogenesis. N Engl J Med (1985) 1.82

Multiple gonococcal opacity proteins are expressed during experimental urethral infection in the male. J Exp Med (1994) 1.80

Sexually transmitted diseases in the People's Republic of China in Y2K: back to the future. Sex Transm Dis (2000) 1.80

Changing prevalence of oral manifestations of human immuno-deficiency virus in the era of protease inhibitor therapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod (2000) 1.79

Functional magnetic resonance imaging of symptom provocation in obsessive-compulsive disorder. Arch Gen Psychiatry (1996) 1.77

The effect of Plasmodium falciparum malaria on HIV-1 RNA blood plasma concentration. AIDS (1999) 1.76

Laparoscopic complications in markedly obese urologic patients (a multi-institutional review) Urology (1996) 1.75

Acquiring simultaneous EEG and functional MRI. Clin Neurophysiol (2000) 1.75

Immune response and vaccine efficiency. Vaccine (1998) 1.74

Antiretroviral-drug concentrations in semen: implications for sexual transmission of human immunodeficiency virus type 1. Antimicrob Agents Chemother (1999) 1.68

Treatment with amprenavir alone or amprenavir with zidovudine and lamivudine in adults with human immunodeficiency virus infection. AIDS Clinical Trials Group 347 Study Team. J Infect Dis (1999) 1.67

Free radicals and phagocytic cells. FASEB J (1995) 1.65

Chancroid, primary syphilis, genital herpes, and lymphogranuloma venereum in Antananarivo, Madagascar. J Infect Dis (1999) 1.64

Serum sensitivity of Neisseria gonorrhoeae: the role of lipopolysaccharide. J Infect Dis (1984) 1.64

A new deal in HIV prevention: lessons from the global approach. Ann Intern Med (1994) 1.63

Adequacy of fellowship training: results of a survey of recently graduated fellows. Clin Infect Dis (2001) 1.63

Molecular typing of Neisseria gonorrhoeae causing repeated infections: evolution of porin during passage within a community. J Infect Dis (1999) 1.62

Quantitation of human immunodeficiency virus type 1 RNA in different biological compartments. J Clin Microbiol (2000) 1.60

Resistance of HIV-1 to antiretroviral agents in blood and seminal plasma: implications for transmission. AIDS (1998) 1.59